Search Result
Results for "
bone resorption inhibitor
" in MedChemExpress (MCE) Product Catalog:
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-114275
-
|
Fungal
Parasite
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation .
|
-
-
- HY-N2532
-
|
VSV
HIV
Proton Pump
Influenza Virus
|
Infection
Inflammation/Immunology
Cancer
|
Diphyllin is an orally active V-ATPase inhibitor (IC50=17 nM) and HIV-1 inhibitor (IC50=0.38 μM). Diphyllin blocks the acidification of osteoclast lysosomes and bone resorption lacunas (IC50=0.6 nM for acid influx inhibition), thereby inhibiting bone resorption. Diphyllin can effectively inhibit osteoclast-mediated bone resorption and has no effect on osteoblastic bone formation. Diphyllin can be used in the research of bone metabolism-related diseases and has the potential to inhibit diseases related to excessive bone resorption .
|
-
-
- HY-B0657
-
Clodronate
|
Apoptosis
|
Others
Cancer
|
Clodronic acid is an orally active bisphosphonate, which is used for researching osteoporosis and diseases associated with excessive bone resorption. Clodronic acid inhibits bone resorption through induction of osteoclast apoptosis. Clodronic acid is effective in the maintenance or improvement of bone mineral density .
|
-
-
- HY-P0090
-
Salmon calcitonin
|
CGRP Receptor
|
Cancer
|
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
|
-
-
- HY-N5023
-
|
Others
|
Metabolic Disease
|
Veraguensin is a lignan compound derived from Magnolia sp.. Veraguensin can inhibit bone resorption
|
-
-
- HY-B0657A
-
Clodronate disodium salt
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Clodronic acid (Clodronate) disodium salt, a first-generation bisphosphonate, is orally active osteoclastic bone resorption inhibitor. Clodronic acid disodium salt can be used in high bone turnover states, Paget ’s disease and osteolytic bone metastases .
|
-
-
- HY-B0119
-
Risedronate sodium
|
Parasite
Apoptosis
|
Infection
Metabolic Disease
Cancer
|
Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC50 of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .
|
-
-
- HY-P0007
-
Carbocalcitonin
|
Drug Intermediate
|
Metabolic Disease
|
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .
|
-
-
- HY-122082
-
|
Apoptosis
|
Inflammation/Immunology
|
Methopterin inhibits osteoclasts proliferation. Methopterin inhibits the activation and bone resorption function of osteoclasts, and induced osteoclasts apoptosis .
|
-
-
- HY-P0090A
-
Salmon calcitonin acetate
|
CGRP Receptor
|
Cancer
|
Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .
|
-
-
- HY-N9331
-
Cimicidanol-3-O-β-d-xyloside
|
Others
|
Metabolic Disease
|
Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .
|
-
-
- HY-122077
-
|
Chloride Channel
|
Metabolic Disease
|
NS5818 is a potent chloride channel inhibitor. NS5818 inhibits acidification and bone resorption. NS5818 has the potential for the research of osteoporosis .
|
-
-
- HY-P4684
-
PTHrP (107–111)
|
PTHR
|
Inflammation/Immunology
|
Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .
|
-
-
- HY-108685
-
Alendronic acid monosodium salt
|
Others
|
Metabolic Disease
Cancer
|
Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .
|
-
-
- HY-122075
-
|
Others
|
Metabolic Disease
|
FR 78844 is a potent and orally active bone resorption inhibitor. FR 78844 has the potential for the research of diabetes associated osteopenia .
|
-
-
- HY-N13219
-
|
Others
|
Metabolic Disease
|
Angelica Extract is an angelica extract, and its components include: Ligustilide. Angelica Extract can effectively inhibit the differentiation of osteoclasts, regulate osteoclastogenesis and/or bone loss. Angelica Extract has the potential to be used in the study of various bone diseases caused by excessive bone resorption. .
|
-
-
- HY-10294
-
SB-462795
|
Cathepsin
|
Metabolic Disease
Cancer
|
Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
|
-
-
- HY-111248
-
|
Nuclear Factor of activated T Cells (NFAT)
c-Fms
|
Others
|
ABD-295, a biphenylsulfide derivative, is an antiresorptive agent, osteoclast inhibitor. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo [1] .
|
-
-
- HY-106431
-
Olpadronate; OLP
|
Others
|
Metabolic Disease
Cancer
|
Olpadronic acid (Olpadronate) is an orally active amino-bisphosphonate and inhibits bone resorption. Olpadronic acid also prevents bone destruction and tumor growth in the skeletal prostate cancer mouse model. Olpadronic acid can be used for research of osteoporosis, malignancies and rheumatoid arthritis .
|
-
-
- HY-B0631
-
|
Bacterial
|
Cancer
|
Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
|
-
-
- HY-P2273
-
|
CGRP Receptor
|
Metabolic Disease
|
Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .
|
-
-
- HY-122082R
-
|
Apoptosis
|
Inflammation/Immunology
|
Methopterin (Standard) is the analytical standard of Methopterin. This product is intended for research and analytical applications. Methopterin inhibits osteoclasts proliferation. Methopterin inhibits the activation and bone resorption function of osteoclasts, and induced osteoclasts apoptosis .
|
-
-
- HY-B0148
-
Risedronate
|
Parasite
Apoptosis
|
Infection
Metabolic Disease
Cancer
|
Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
|
-
-
- HY-110318
-
|
CXCR
|
Inflammation/Immunology
Cancer
|
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
|
-
-
- HY-A0020
-
ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
|
VD/VDR
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
|
-
-
- HY-126825
-
|
Phosphatase
|
Metabolic Disease
|
NE21650 potently inhibits farnesyl diphosphate (FPP) synthase. NE21650 is a weak inhibitor of isopentenyl diphosphate (IPP) isomerase. NE21650 is a potent inhibitor of protein prenylation in osteoclasts and macrophages and bone resorption in vitro .
|
-
-
- HY-123370
-
|
Proton Pump
|
Metabolic Disease
Cancer
|
FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
|
-
-
- HY-P1288
-
PKC fragment (530-558)
|
PKC
|
Others
|
Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .
|
-
-
- HY-164587
-
|
DOCK
|
Metabolic Disease
|
E197 is the inhibitor for DOCK5 that destroys the podosome belt structure of osteoclasts, thereby inhibiting the bone resorption (IC50=3.44 μM in human osteoclast). E197 inhibits the Rac in DOCK5 expressing HEK293 cell with an IC50 of 36 μM. E197 prevents the bone loss in mouse ovariectomized models .
|
-
-
- HY-106431R
-
Olpadronate (Standard); OLP (Standard)
|
Others
|
Metabolic Disease
Cancer
|
Olpadronic acid (Standard) is the analytical standard of Olpadronic acid. This product is intended for research and analytical applications. Olpadronic acid (Olpadronate) is an orally active amino-bisphosphonate and inhibits bone resorption. Olpadronic acid also prevents bone destruction and tumor growth in the skeletal prostate cancer mouse model. Olpadronic acid can be used for research of osteoporosis, malignancies and rheumatoid arthritis .
|
-
-
- HY-164532
-
|
Chloride Channel
|
Metabolic Disease
|
NS3736 is an orally effective chloride channel inhibitor that can be used for the research of osteoporosis. NS3736 targets the CIC-7 channel in osteocytes, blocks osteoclast acidification and resorption in vitro, with IC50=30 μM. In a rat model of ovariectomy-induced osteoporosis, NS3736 can enhance bone strength and bone density .
|
-
-
- HY-125064
-
|
Src
|
Cancer
|
AP22408 is a nonpeptide inhibitor against Src SH2 with an IC50 value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .
|
-
-
- HY-P4798
-
Human PTHrP(107-111) amide
|
PTHR
|
Others
|
Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) (Human PTHrP (107-111) amide) is a C-terminal parathyroid hormone-related protein fragment that can inhibit bone resorption .
|
-
-
- HY-149149
-
|
Bacterial
|
Infection
Metabolic Disease
Cancer
|
Incadronic acid inhibits growth of Dictyostelium discoideum with an IC50 of 1.6 μM. Incadronic acid binds the farnesyl diphosphate synthase (FPPS) in Leishmania major with the Ki of 23 nM. Incadronic acid inhibits the bone resorption and reduces bone loss, that can be used in osteoporosis research. Incadronic acid inhibits the proliferation of cells RAW264.7, PC-3 and MCF-7 with IC50 of 48 to 228.6 µM .
|
-
-
- HY-B0631S
-
|
Isotope-Labeled Compounds
|
Cancer
|
Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
|
-
-
- HY-108685S
-
Alendronic acid-d4 monosodium salt
|
Isotope-Labeled Compounds
Others
|
Metabolic Disease
Cancer
|
Alendronate-d4 (sodium) (Alendronic acid-d4 (monosodium salt)) is deuterium labeled Alendronate sodium. Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .
|
-
-
- HY-P0322
-
EMD 56574
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
|
-
-
- HY-129337
-
|
Antibiotic
Fungal
Apoptosis
|
Infection
Cancer
|
Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity .
|
-
-
- HY-A0020R
-
|
VD/VDR
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Eldecalcitol (Standard) is the analytical standard of Eldecalcitol. This product is intended for research and analytical applications. Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
|
-
-
- HY-B1246
-
|
Bacterial
Proton Pump
|
Infection
|
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
|
-
-
- HY-12398
-
|
VD/VDR
|
Metabolic Disease
Inflammation/Immunology
|
TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
|
-
-
- HY-B0148R
-
Risedronate (Standard)
|
Parasite
Apoptosis
|
Infection
Metabolic Disease
Cancer
|
Risedronic acid (Standard) (Risedronate (Standard)) is the analytical standard of Risedronic acid (HY-B0148). This product is intended for research and analytical applications. Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM).
|
-
-
- HY-P0322A
-
EMD 56574 TFA
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
|
-
-
- HY-B0515B
-
|
Apoptosis
|
Metabolic Disease
Cancer
|
Ibandronate Sodium is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
|
-
-
- HY-P0090S
-
Salmon calcitonin-13C6,15N4 TFA
|
CGRP Receptor
|
Metabolic Disease
|
Calcitonin- 13C6, 15N4 (salmon) (Salmon calcitonin- 13C6, 15N4) TFA is 13C and 15N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption .
|
-
-
- HY-B0302
-
Etidronate; HEDPA; HEDP
|
Apoptosis
|
Metabolic Disease
Cancer
|
Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .
|
-
-
- HY-B0148S
-
Risedronate-d4
|
Isotope-Labeled Compounds
Parasite
Apoptosis
|
Infection
Metabolic Disease
Cancer
|
Risedronic acid-d4 (Risedronate-d4) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
|
-
-
- HY-N1956
-
|
NF-κB
|
Metabolic Disease
|
Rubiadin-1-methyl ether is a natural anthraquinone isolated from Morinda officinalis How, and inhibits osteoclastic bone resorption via inhibition on the phosphorylation of NF-κB p65 and the degradation of IκBα as well as decrease in the nuclear translocation of p65 .
|
-
-
- HY-N6084
-
α-Lupulic acid
|
COX
GABA Receptor
Apoptosis
|
Cardiovascular Disease
|
Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent cyclooxygenase-2 (COX-2) inhibitor. Humulone acts as a positive modulator of GABAA receptor at low micromolar concentrations. Humulone is an inhibitor of bone resorption. Humulone possesses antioxidant, anti-angiogenic and apoptosis-inducing properties .
|
-
-
- HY-B0515
-
BM-210955; RPR-102289A
|
Apoptosis
|
Metabolic Disease
Cancer
|
Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
|
-
- HY-103352
-
L-235
|
Cathepsin
|
Metabolic Disease
|
L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC50 of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (Ki=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (Ki=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss .
|
-
- HY-B0302A
-
Etidronate disodium; HEDPA disodium; HEDP disodium
|
Apoptosis
|
Metabolic Disease
Cancer
|
Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
|
-
- HY-149852
-
|
Others
|
Inflammation/Immunology
|
Anti-osteoporosis agent-3 (Compound 11), a PMSA derivative, is an anti-osteoporosis agent. Anti-osteoporosis agent-3 inhibits osteoclastogenesis with an IC50 value of 322.9 nM in vitro. Anti-osteoporosis agent-3 also blocks the formation of F-action belts and bone resorption .
|
-
- HY-123503
-
|
JNK
NF-κB
|
Neurological Disease
Inflammation/Immunology
|
Salicortin, a phenolic glycoside, has been isolated from many plants such as Populus and Salix species. Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating JNK and NF-κB/NFATc1 signaling pathways. Salicortin has anti-amnesic, anti-adipogenic, and immune-modulatory activity .
|
-
- HY-B1246R
-
|
Bacterial
Proton Pump
|
Infection
|
Thonzonium (bromide) (Standard) is the analytical standard of Thonzonium (bromide). This product is intended for research and analytical applications. Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
|
-
- HY-P1189
-
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
|
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
|
-
- HY-P1189A
-
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
|
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
|
-
- HY-161869
-
|
Histone Methyltransferase
|
Metabolic Disease
|
LSD1-IN-32 (compound 11e) is a potent LSD1 inhibitor with an IC50 value of 0.99 µM. LSD1-IN-32 inhibits RANKL-induced osteoclastogenesis, bone resorption and F-actin belt formation. LSD1-IN-32 has the potential for the research of osteoporosis .
|
-
- HY-112499
-
Vitamin K2-7; Vitamin K2(35); Vitamin MK-7
|
Others
|
Cardiovascular Disease
|
Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
|
-
- HY-50887
-
|
Cathepsin
|
Metabolic Disease
|
L-873724 is a potent, orally bioavailable, selective and reversible non-basic cathepsin K inhibitor, with IC50s of 0.2, 178, 264, and 5239 nM for cathepsin K, cathepsin S, cathepsin L, cathepsin B, respectively . L-873724 also exhibits an IC50 of 0.5 nM for rabbit cathepsin K. L-873724 inhibits bone resorption .
|
-
- HY-B0746
-
dl-Flurbiprofen sodium
|
Endogenous Metabolite
|
Inflammation/Immunology
|
Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibiting carbonic anhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
|
-
- HY-169703
-
|
RANKL/RANK
p38 MAPK
Akt
NF-κB
|
Inflammation/Immunology
|
SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis .
|
-
- HY-B0515R
-
BM-210955 (Standard); RPR-102289A (Standard)
|
Apoptosis
|
Cancer
|
Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) (Standard) is the analytical standard of Ibandronate Sodium Monohydrate (HY-B0515). This product is intended for research and analytical applications. Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
|
-
- HY-103352R
-
L-235 (Standard)
|
Cathepsin
|
Metabolic Disease
|
L-006235 (Standard) is the analytical standard of L-006235. This product is intended for research and analytical applications. L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC50 of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (Ki=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (Ki=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss .
|
-
- HY-N4288
-
|
Glutathione Peroxidase
Cathepsin
Phosphatase
|
Inflammation/Immunology
Cancer
|
4-Methylesculetin is an orally active coumarin derivative, with potent anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase activity. 4-Methylesculetin protects bone resorption by reducing the elevated levels of bone-joint exoglycosidases, cathepsin-D and tartrate resistant acid phosphatases. 4-Methylesculetin ameliorats the upregulated non-enzymatic inflammatory markers like TNF-α, IL-1β, IL-6, COX-2 and PGE2, which is promising for research of inflammatory diseases .
|
-
- HY-112499R
-
Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)
|
Endogenous Metabolite
|
Cardiovascular Disease
|
Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
|
-
- HY-N0721
-
-
- HY-B0302AR
-
|
Apoptosis
|
Metabolic Disease
Cancer
|
Etidronic acid (disodium) (Standard) is the analytical standard of Etidronic acid (disodium). This product is intended for research and analytical applications. Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
|
-
- HY-135594
-
|
Estrogen Receptor/ERR
|
Metabolic Disease
|
4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A .
|
-
- HY-135595
-
|
Estrogen Receptor/ERR
Drug Metabolite
|
Metabolic Disease
|
6-Raloxifene-β-D-glucopyranoside, a derivative of Raloxifene, is a benzothiophene glucuronidated at the 6' postion. 6-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 6'-Raloxifene-β-D-glucopyranoside, compound Ia, is extracted from patent US5567820A .
|
-
- HY-162280
-
|
PROTACs
RANKL/RANK
Nuclear Factor of activated T Cells (NFAT)
Btk
|
Cancer
|
PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca 2+-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .
|
-
- HY-164036R
-
|
Antibiotic
Bacterial
|
Infection
|
Flurbiprofen (sodium) (Standard) is the analytical standard of Flurbiprofen (sodium). This product is intended for research and analytical applications. Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibiting carbonic anhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
|
-
- HY-N1746
-
2'-O-Methylkurarinone
|
RANKL/RANK
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
(2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .
|
-
- HY-168090
-
|
p38 MAPK
NF-κB
RANKL/RANK
|
Endocrinology
|
Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC50 value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .
|
-
- HY-B0746R
-
|
Endogenous Metabolite
|
Inflammation/Immunology
|
Flurbiprofen (sodium) (Standard) is the analytical standard of Flurbiprofen (sodium). This product is intended for research and analytical applications. Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibiting carbonic anhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
|
-
- HY-B2097
-
YM 175; Bisphonal
|
Farnesyl Transferase
|
Metabolic Disease
|
Incadronate disodium (YM 175) is a bisphosphonate with strong inhibitory activity on bone resorption. Incadronate disodium indirectly stimulates renal 25-hydroxyvitamin D-1-hydroxylase by increasing circulating parathyroid hormone. Incadronate disodium, a cholesterol-lowering agent, is a potent inhibitor of rat liver microsomal squalene synthase (Ki=57 nM). Incadronate disodium inhibits sterol biosynthesis in mouse macrophage J774 cells (IC50=64 μM). Incadronate disodium has the potential for malignant tumors research .
|
-
- HY-N0721R
-
Neoandrographiside (Standard)
|
Reference Standards
ERK
p38 MAPK
JNK
NF-κB
PI3K
PPAR
GSK-3
NO Synthase
Reactive Oxygen Species
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
Neoandrographolide (Standard) is the analytical standard of Neoandrographolide. This product is intended for research and analytical applications. Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0090
-
Salmon calcitonin
|
CGRP Receptor
|
Cancer
|
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
|
-
- HY-P2273
-
|
CGRP Receptor
|
Metabolic Disease
|
Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .
|
-
- HY-P0322
-
EMD 56574
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
|
-
- HY-P0090S
-
Salmon calcitonin-13C6,15N4 TFA
|
CGRP Receptor
|
Metabolic Disease
|
Calcitonin- 13C6, 15N4 (salmon) (Salmon calcitonin- 13C6, 15N4) TFA is 13C and 15N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption .
|
-
- HY-P0007
-
Carbocalcitonin
|
Drug Intermediate
|
Metabolic Disease
|
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .
|
-
- HY-P0090A
-
Salmon calcitonin acetate
|
CGRP Receptor
|
Cancer
|
Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .
|
-
- HY-P4684
-
PTHrP (107–111)
|
PTHR
|
Inflammation/Immunology
|
Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .
|
-
- HY-P1288
-
PKC fragment (530-558)
|
PKC
|
Others
|
Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .
|
-
- HY-P4798
-
Human PTHrP(107-111) amide
|
PTHR
|
Others
|
Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) (Human PTHrP (107-111) amide) is a C-terminal parathyroid hormone-related protein fragment that can inhibit bone resorption .
|
-
- HY-P0322A
-
EMD 56574 TFA
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
|
-
- HY-P10299
-
|
Peptides
|
Others
|
Calcitonin, porcine inhibits 1,25 (OH)2D3-stimulated porcine osteoclast differentiation. Calcitonin is a polypeptide hormone that can lower serum calcium by decreasing calcium reabsorption in the kidney and inhibiting osteoclastic bone resorption. Calcitonin, porcine can be used for research of hypercalcemia .
|
-
- HY-P1189
-
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
|
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
|
-
- HY-P1189A
-
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
|
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9982
-
|
Inhibitory Antibodies
|
Endocrinology
Cancer
|
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis .
|
-
- HY-P99186
-
|
Inhibitory Antibodies
|
Others
|
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0631S
-
|
Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
|
-
-
- HY-P0090S
-
|
Calcitonin- 13C6, 15N4 (salmon) (Salmon calcitonin- 13C6, 15N4) TFA is 13C and 15N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption .
|
-
-
- HY-108685S
-
|
Alendronate-d4 (sodium) (Alendronic acid-d4 (monosodium salt)) is deuterium labeled Alendronate sodium. Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .
|
-
-
- HY-B0148S
-
|
Risedronic acid-d4 (Risedronate-d4) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: